Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.
You may also be interested in...
Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.
Johnson & Johnson is the first big pharmaceutical company to report first quarter financial results, and investors across the industry are interested in hearing how the COVID-19 pandemic is impacting the sector's fundamental business dynamics.
Sage will initiate three new trials to support FDA approval of the drug for post-partum depression and major depressive disorder, with data anticipated in 2021.